Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone212-733-2323
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$53.65 billion
Profitability
Miscellaneous
Employees92,400
Next Earnings Date10/29/2019 (Confirmed)
OptionableOptionable
Pfizer (NYSE:PFE) Frequently Asked Questions
What is Pfizer's stock symbol?
Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."
How often does Pfizer pay dividends? What is the dividend yield for Pfizer?
Pfizer announced a quarterly dividend on Tuesday, September 24th. Stockholders of record on Friday, November 8th will be given a dividend of $0.36 per share on Monday, December 2nd. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.97%. The ex-dividend date of this dividend is Thursday, November 7th. View Pfizer's Dividend History.
How will Pfizer's stock buyback program work?
Pfizer announced that its Board of Directors has authorized a stock repurchase program on Friday, December 14th 2018, which authorizes the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 3.8% of its stock through open market purchases. Stock buyback programs are often an indication that the company's leadership believes its stock is undervalued.
How were Pfizer's earnings last quarter?
Pfizer Inc. (NYSE:PFE) issued its quarterly earnings data on Monday, July, 29th. The biopharmaceutical company reported $0.80 EPS for the quarter, beating the consensus estimate of $0.75 by $0.05. The biopharmaceutical company had revenue of $13.26 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The business's quarterly revenue was down 1.5% on a year-over-year basis. During the same period last year, the firm earned $0.77 earnings per share. View Pfizer's Earnings History.
When is Pfizer's next earnings date?
How can I listen to Pfizer's earnings call?
Pfizer will be holding an earnings conference call on Tuesday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Pfizer issued on next quarter's earnings?
Pfizer issued an update on its FY19 earnings guidance on Monday, July, 29th. The company provided earnings per share guidance of $2.76-2.86 for the period, compared to the Thomson Reuters consensus estimate of $2.91. The company issued revenue guidance of $50.5-52.5 billion, compared to the consensus revenue estimate of $53.45 billion.
What price target have analysts set for PFE?
15 Wall Street analysts have issued twelve-month price targets for Pfizer's stock. Their predictions range from $36.00 to $55.00. On average, they anticipate Pfizer's share price to reach $45.71 in the next year. This suggests a possible upside of 26.0% from the stock's current price. View Analyst Price Targets for Pfizer.
What is the consensus analysts' recommendation for Pfizer?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 11 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pfizer.
What are Wall Street analysts saying about Pfizer stock?
Here are some recent quotes from research analysts about Pfizer stock:
- 1. According to Zacks Investment Research, "The Consumer Healthcare joint venture with Glaxo, the Array acquisition and the pending merger of Upjohn unit with Mylan, if successful, will make Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. The smaller Pfizer should see better revenue growth as the Lyrica LOE cliff will go away. Pfizer expects continued strong growth of key brands like Ibrance and Eliquis and biosimilars to drive sales in the second half. Pfizer is also strengthening its pipeline and hopes to launch new innovative medicines in the next five years, which can drive long-term growth. However, currency headwinds, weak sales in the sterile injectables portfolio, pricing pressure and some recent negative product developments for Prevnar and Xeljanz, are top-line headwinds. Shares have underperformed the industry this year so far. " (10/1/2019)
- 2. Cantor Fitzgerald analysts commented, "We reiterate our OW rating and think respectable earnings growth, driven by Innovative Medicines, pipeline advancements, and return of capital to PFE’s shareholders — above the industry average — are all underappreciated. Therefore, we believe multiple expansion and upward earnings revisions should drive PFE shares higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $53." (2/19/2019)
Has Pfizer been receiving favorable news coverage?
News headlines about PFE stock have been trending negative this week, InfoTrie Sentiment reports. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Pfizer earned a daily sentiment score of -2.8 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Pfizer.
Are investors shorting Pfizer?
Pfizer saw a drop in short interest in September. As of September 30th, there was short interest totalling 47,830,000 shares, a drop of 18.3% from the August 30th total of 58,540,000 shares. Based on an average daily trading volume, of 24,780,000 shares, the days-to-cover ratio is currently 1.9 days. Currently, 0.9% of the shares of the company are short sold. View Pfizer's Current Options Chain.
Who are some of Pfizer's key competitors?
Some companies that are related to Pfizer include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Sanofi (SNY), AbbVie (ABBV), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY).
What other stocks do shareholders of Pfizer own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Pfizer investors own include AT&T (T), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Verizon Communications (VZ), General Electric (GE), Intel (INTC), Exxon Mobil (XOM), Bank of America (BAC), Merck & Co., Inc. (MRK) and Walt Disney (DIS).
Who are Pfizer's key executives?
Pfizer's management team includes the folowing people:
- Mr. Ian C. Read, Exec. Chairman (Age 65)
- Mr. Albert Bourla D.V.M., DVM, Ph.D., CEO & Director (Age 57)
- Mr. Frank A. D'Amelio, CFO & EVP of Global Supply & Bus. Operations (Age 61)
- Dr. Mikael Dolsten, Chief Scientific Officer & Pres of Worldwide Research, Devel. and Medical (Age 60)
- Mr. John D. Young, Group Pres & Chief Bus. Officer (Age 54)
Who are Pfizer's major shareholders?
Pfizer's stock is owned by a number of of retail and institutional investors. Top institutional investors include Hexavest Inc. (0.05%), Meyer Handelman Co. (0.02%), Gulf International Bank UK Ltd (0.02%), Manning & Napier Group LLC (0.02%), State of Alaska Department of Revenue (0.02%) and Welch & Forbes LLC (0.02%). Company insiders that own Pfizer stock include Alexander R Mackenzie, Charles H Hill, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Pfizer Inc, Rady A Johnson, Sally Susman, Scott Gottlieb and W Don Cornwell. View Institutional Ownership Trends for Pfizer.
Which institutional investors are selling Pfizer stock?
PFE stock was sold by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, State of Alaska Department of Revenue, Hexavest Inc., American National Bank, Crossmark Global Holdings Inc., First American Trust FSB, Enterprise Bank & Trust Co and TIAA FSB. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Dawn Rogers, Douglas M Lankler, Frank A Damelio, Mikael Dolsten and Rady A Johnson. View Insider Buying and Selling for Pfizer.
Which institutional investors are buying Pfizer stock?
PFE stock was acquired by a variety of institutional investors in the last quarter, including Park National Corp OH, Accurate Investment Solutions Inc., Pacer Advisors Inc., Community Trust & Investment Co., Fulton Bank N.A., Rockland Trust Co., Manning & Napier Group LLC and Cliftonlarsonallen Wealth Advisors LLC. Company insiders that have bought Pfizer stock in the last two years include Pfizer Inc and Scott Gottlieb. View Insider Buying and Selling for Pfizer.
How do I buy shares of Pfizer?
Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Pfizer's stock price today?
One share of PFE stock can currently be purchased for approximately $36.27.
How big of a company is Pfizer?
Pfizer has a market capitalization of $200.61 billion and generates $53.65 billion in revenue each year. The biopharmaceutical company earns $11.15 billion in net income (profit) each year or $3.00 on an earnings per share basis. Pfizer employs 92,400 workers across the globe.View Additional Information About Pfizer.
What is Pfizer's official website?
How can I contact Pfizer?
Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.
MarketBeat Community Rating for Pfizer (NYSE PFE)
MarketBeat's community ratings are surveys of what our community members think about Pfizer and other stocks. Vote "Outperform" if you believe PFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PFE will underperform the S&P 500 over the long term. You may vote once every thirty days.
